Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | HINT1 | P49773 | 3/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357437 | 0.86 | POLB (0.49) | POLBPOLA1PNPHINT1P2RY2 | |
| SCHEMBL30712246 | 0.86 | POLB (0.58) | POLBPNPP2RY2P2RY4P2RY6 | |
| SCHEMBL29546691 | 0.85 | POLB (0.57) | POLBPNPP2RY2P2RY4P2RY6 | |
| SCHEMBL3503649 | 0.84 | POLB (0.56) | POLBPNPP2RY2P2RY4P2RY6 | |
| SCHEMBL3501824 | 0.83 | POLB (0.55) | POLBPNPP2RY2P2RY4P2RY6 | |
| SCHEMBL3148826 | 0.83 | POLB (0.55) | POLBPNPP2RY2P2RY4P2RY6 | |
| SCHEMBL5346949 | 0.81 | POLB (0.48) | POLBPOLA1PNPHINT1P2RY2 | |
| SCHEMBL28094790 | 0.81 | POLB (0.59) | POLBPNPP2RY2P2RY4P2RY6 | |
| SCHEMBL3779342 | 0.81 | POLB (0.55) | POLBPNPHINT1P2RY2P2RY4 | |
| SCHEMBL6535196 | 0.81 | EHMT1 (0.55) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169765-B1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743782-B1 | ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY | WELLSTAT THERAPEUTICS CORPORATION | 2004-06-01 | — | — | US | disclosed |
| EP-0712629-B1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6348451-B1 | WOUND HEALING AGENTS FOR ANIMALS | PRO-NEURON, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6306834-B1 | METHODS OF TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR, COMPRISING ADMINISTERING THE COMPOSITIONS OF THE PRESENT INVENTION TO AN ANIMAL. | PRO-NEURON, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6297222-B1 | TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, AND METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | PRO-NEURON, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6103701-A | ADMINISTERING COMPOSITIONS COMPRISING ACYL DERIVATIVES OF 2'-DEOXYRIBONUCLEOSIDES; FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | VON BORSTEL REID WARREN (US) | 2000-08-15 | — | — | US | disclosed |
| US-6020322-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6020320-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0355131-B1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO NEURON INC (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0712629-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0355131-A1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO-NEURON, INC. (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | POLB 46/4885POLA1 168/4885PNP 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.